Anwita Biosciences is a San Francisco Bay Area startup company specializing in antibodies and fusion proteins for therapies in oncology and auto-immune disease. Anwita is dedicated to developing tissue-specific drug delivery to improve their therapeutic indices.
Anwita has state-of-the-art antibody discovery technology. We utilize an innovative screening platform for antibody discovery, resulting in efficient identification of functional antibodies.
Anwita develops ex-vivo disease models using tissue and cancer organoids to more efficiently screen protein therapeutics. These disease models more accurately simulate in vivo pharmacology compared to traditional cell lines thereby increasing the likelihood of translational success.